A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants (NCT03253263)
A Phase 2b, Multicenter, Randomized, Open-label, Two-Arm Study to Evaluate the Clinical Efficacy and Safety of OHB-607 Compared to Standard Neonatal Care for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease of Prematurity
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Who can join: Review the eligibility criteria below.
Location: Arkansas Children's Hospital — Little Rock, Arkansas
Age range: 0 Hours to 24 Hours
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- Arkansas Children's Hospital — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Children's Hospital of Orange County — California City, California
- Cedars Sinai Medical Center — Los Angeles, California
- US Davis — Sacramento, California
- Jackson Memorial Hospital — Miami, Florida
- Tampa General Hospital — Tampa, Florida
- University of Illinois at Chicago — Chicago, Illinois
- Riley Hospital for Children — Indianapolis, Indiana
- Memorial Hospital of South Bend — South Bend, Indiana
- University of Louisville Hospital — Louisville, Kentucky
- Ochsner Baptist Medical Center — New Orleans, Louisiana
- Tufts Medical Center — Boston, Massachusetts
- Children's Minnesota - Children's Hospital and Clinics - St. Paul — Saint Paul, Minnesota
- Children's Minnesota - Children's Hospital and Clinics — Saint Paul, Minnesota
- University of Mississippi Medical Center — Jackson, Mississippi
- University of Rochester — Rochester, New York
- Maria Fareri Children's Hospital — Valhalla, New York
- Oklahoma Children's Hospital - PIN — Oklahoma City, Oklahoma
- Medical University of South Carolina Children Hospital — Charleston, South Carolina
- Texas Children's Hospital — Houston, Texas
- UT Health Science Center — San Antonio, Texas
- UVA Children's Hospital — Charlottesville, Virginia
- Virginia Commonwealth University - Children's Hospital of Richmond at VCU — Richmond, Virginia
- Royal Hospital for Women — Randwick, New South Wales
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Bronchopulmonary Dysplasia
- Enteral High-dose DHA Supplementation on Bronchopulmonary Dysplasia in Very Preterm Infants: a Collaborative Study — Québec, Quebec
- Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia — Gloucester, Ontario
- Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia — Palo Alto, California
- MRI in BPD Subjects — Cincinnati, Ohio
- Ventilator Pressure and Optimization of Compliance and Hemodynamics — Birmingham, Alabama
Explore by condition: All Bronchopulmonary Dysplasia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.